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Abstract
A single, i.p. dose of bleomycin was administered simultaneously with [35S]methionine to 4-month-old p53 wild type (+/+)
and p53 heterozygous (+/3) C57BL/6 mice. Following a period of 3.5 h from dosing, the bone marrow nuclei were examined
by two-dimensional PAGE and fluorography for induction of stress proteins (sps). Eight sps ranging from 22 000 to 100 000
Mr were synthesized in p53+/3 and p53+/+ mice following elicitation by bleomycin. No quantitative or qualitative
differences were observed in sp expression in these two groups of animals. In a second experiment, three doses of retinoic acid
were given i.p. to p53+/3 and p53+/+ mice over a 36 h period. The p53 isoforms in bone marrow nuclei from these mice were
analyzed by PAGE for incorporation of [35S]methionine following retinoic acid injections. Quantitative and qualitative
alterations in p53 isotypes were substantially increased in p53+/+ as compared with p53+/3 mice. The increased complexity
in the synthesis patterns in both groups of dosed mice consisted of additional isoforms possessing more acidic isoelectric
values. In an in vitro binding assay, individual p53 isoforms demonstrated varying degrees of association with sps 25a, 70i,
72c and 90 which was consistently greater in p53+/+ mice. Both the synthesis and binding of isoforms were greater in G1 than
in S+G2 phase, in both groups of animals, reflecting a cell cycle regulated mechanism for these events. Collectively, these data
implied that the synthesis and the binding characteristics of p53 isoforms with sps were enhanced in the p53+/+ mice relative
to the p53+/3 mouse; however, sp labeling was not affected by p53 genotype. ß 1999 Elsevier Science B.V. All rights
reserved.
1. Introduction
Retinoic acid (RA), an active metabolite of vita-
min A, has been shown to alter cellular proliferation,
induce apoptosis [1], and initiate cell di¡erentiation
both in vivo and in vitro [2^5]. In vitro cell di¡er-
entiation generally begins immediately and is com-
pleted within 1 week from time of dosing. This is
accompanied by a progressive reduction in cell divi-
sion and the eventual halting of replication (terminal
di¡erentiation) [2^5]. In both rat bone marrow [2]
and HL 60 cells [6,7], these events are associated
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with alterations in protein expression and phospho-
rylation and in cellular morphology [8]. RA was
shown to induce a temporary reduction in cell cy-
cling in rat bone marrow cells [2]. Associated with
this event was the induction of p53 as re£ected by
robust synthesis and phosphorylation of p53 iso-
types.
P53 is a member of the family of cell cycle regu-
lator proteins which are di¡erentially synthesized and
phosphorylated [9]. It is believed that phosphoryla-
tion of p53 isoforms functions to suppress cell pro-
liferation by restricting aberrant cell progression at
the G1/S interface [10^12]. P53 binds to DNA in a
sequence-speci¢c manner and induces the transacti-
vation of genes involved in G1 cell cycle arrest, DNA
repair and apoptosis (reviewed in [11^13]). Recently
it has been shown that p53 not only binds to DNA,
but also forms a complex with several stress proteins
(sps)/heat shock proteins when immunoprecipitated.
It has been suggested that this phenomenon repre-
sents a non-ionic physical association of these diverse
proteins [13^15].
In view of the fact that p53 expression is cell cycle
regulated, we sought to determine the relative level of
expression of the p53 isoforms in the various phases
of the cell cycle. In addition, we measured the rela-
tive binding e⁄ciency of the p53 isoforms with a
series of classical sps as a means of determining
whether the degree of phosphorylation of p53 af-
fected this interaction. Finally, these experiments
were conducted in both p53+/+ and p53+/3 animals
to determine whether the expression of the p53 iso-
forms and their binding with sps was similar in the
two genotypes of mouse.
2. Materials and methods
2.1. Animals, treatments, 35S-labeling in vivo, and
tissue collection
Male p53 wild-type (p53+/+) and p53 heterozygous
(p53+/3) mice (Taconic Farms), 4 months of age,
were housed and fed standard diets ad libitum. The
animals were divided into six treatment groups: (1)
p53+/+ control animals, (2) p53+/3 control animals,
(3) p53+/+ animals injected intraperitoneally 3.5 h
prior to sacri¢ce with bleomycin (40 mg/kg body
weight, Sigma, St. Louis, MO), (4) p53+/3 animals
similarly injected with bleomycin (BL), (5) p53+/+
animals injected i.p. three times at 12 h intervals
over 36 h with all-trans-retinoic acid (150 mg/kg
body weight dissolved in corn oil, Eastman Kodak,
Rochester, NY), and (6) p53+/3 animals similarly
injected with RA. Subsequently following the pre-
scribed exposures to BL or RA, each treated or
control animal was injected i.p. with [35S]methionine
(1.0 mCi/100 g body mass, speci¢c activity 1170 Ci/
mmol, Amersham, Arlington Heights, IL) dissolved
in 0.5 ml Hanks’ balanced salt solution (HBSS).
After a 3 h pulse-labeling period to allow metabolic
incorporation of [35S]methionine into proteins, the
animals were injected i.p. 30 min prior to sacri¢ce
with excess non-radioactive L-methionine dissolved
in HBSS. Treated and control animals were sacri¢ced
by CO2 asphyxiation and bone marrow tissue was
removed from the long bones [16].
2.2. Isolation, staining and sorting of nuclei
Each sample of bone marrow cells, extruded from
leg long bones by syringe pressure [16], was diluted
to 1.5U106 cells/ml in Vindelov propidium iodine
(PI) staining solution [17]. Outer cell membranes
were disrupted by this technique, but not nuclear
membranes. Thus, PI-stained nuclei were released
for DNA analysis and sorting by £ow cytometry.
Fluorescence-activated cell sorting (FACS) was
used to electrostatically sort nuclei [18] into two pop-
ulations, G0+G1 and S+G2/M, on the basis of DNA
quantity (PI £uorescence) populations into individual
McLeod chambers [18]. These sorted fractions con-
stituted the nuclear samples used for protein extrac-
tion [19]. A typical histogram of nuclear £uorescence
used as a standard for partition sorting is shown
elsewhere [21,22].
2.3. Extraction of proteins from sorted nuclei
Centrifugation of the McLeod chambers at 800Ug
for 10 min pelleted the various nuclear populations
[17], from which nuclear proteins were extracted us-
ing an imidazole extracting bu¡er (500 000 nuclei/
10 Wl) as described previously. After centrifugation
of the nuclear extract in a Beckman AirFuge (Beck-
man Instruments, Palo Alto, CA) at 100 000Ug for
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1 h at 2‡C [17], the supernatant was dialyzed against
the ¢rst dimension (cathodic IEF) electrophoresis
bu¡er [20]. Protein concentration was determined
by the method of Bramhall [23] as described else-
where [19,24].
2.4. Electrophoresis and extraction of nuclear proteins
from gels
Two-dimensional PAGE was performed in either
an ultra-micro electrophoresis apparatus (UMEA)
manufactured in-house [25] or a conventional Bio-
Rad 220 electrophoresis unit (Bio-Rad, Richmond,
CA). UMEA was used for analysis of protein syn-
thesis and for biochemical evaluation of proteins,
while the Bio-Rad 220 unit was used in preparative
procedures requiring the extraction of proteins from
gels. In UMEA, proteins were separated in the ¢rst
dimension in 25 Wl capillary tubes by isoelectric
points (pI), and in the second dimension by relative
molecular mass (Mr) in 10% acrylamide-SDS [26]
slab gels (35U25 mm) as modi¢ed by Ratz et al.
[27]. Radiolabeled bone marrow proteins (500 ng of
protein in 3 Wl) were applied to the ¢rst-dimension
tube gel of UMEA. This was followed by second-
dimension PAGE and £uorography of the slab gel
[28].
Individual proteins for biochemical analysis were
extracted electrophoretically from gel plugs taken
from the second-dimension slab (220 unit) and ex-
tracted in an ISCO protein isolation-concentrator
‘little blue tank’ (ISCO, Lincoln, NE) [19,29,30].
SDS was removed from the proteins during extrac-
tion [19,31].
2.5. Immunoblot analysis of stress protein expression
Bone marrow cells were harvested from p53(+/+)
mice injected i.p. with 40 mg BL/kg body mass 3.5 h
prior to sacri¢ce. No [35S]methionine was adminis-
tered to these animals. Nuclei were prepared and
nuclear proteins were extracted then dialyzed against
cathodic IEF electrophoresis bu¡er as described
above. Nuclear proteins were separated using two-
dimensional PAGE in UMEA [25]. Slab gels were
equilibrated with 25 mM Tris, 192 mM glycine,
20% methanol and the proteins were electrophoreti-
cally transferred to nitrocellulose membranes
(Hoe¡er) using an ultra-micro transblot electropho-
retic cell [30,35,36]. Blotted nitrocellulose membranes
were blocked using 3% BSA in phosphate bu¡ered
saline bu¡er (PBS). Commercially available mouse
primary antibodies were used according to the sup-
plier’s recommendations. Polyclonal mouse antibod-
ies speci¢c for sp (hsp) 90 were obtained from A⁄n-
ity BioReagents (Neshamic Station, NJ). Mouse
monoclonal antibodies speci¢c for sp 100, sp 70i (in-
ducible form 70 000 Mr), 72c (constitutive form
72 000 Mr), and sp 25 were obtained from StressGen
(Victoria, BC). Vimentin-speci¢c monoclonal anti-
bodies were obtained from Boehringer Mannheim
(Indianapolis, IN). Polyclonal antibodies for sps 22
and 23 and the actin isoform, A3, were prepared in
our laboratory from the spleen cells of immunized
mice and these antibodies were used at 1 Wg/100 Wl.
The appropriate primary antibodies, or mixtures of
antibodies, were diluted as indicated and incubated
with the nitrocellulose blots for 5 h then washed ¢ve
times with 0.05% Tween 20 dissolved in PBS (PBS-
T). Sheep anti-mouse 35S-labeled secondary antibod-
ies obtained from Amersham were diluted according
to the supplier’s recommendations and incubated
with the nitrocellulose blots for 5 h. The nitrocellu-
lose blots were washed ¢ve times as before and the
washed blots were placed against X-ray ¢lm for £u-
orographic detection [28].
2.6. Isolation of p53 from nuclear and cytoplasmic
fractions
Bone marrow nuclei (2U106/100 Wl of bu¡er) col-
lected from G0+G1 and S+G2 populations were lysed
with a protein extraction bu¡er composed of 50 mM
NaCl, 50 mM NaF, 0.1 mM sodium vanadate, 2 mM
EDTA and 0.4% NP-40 with 100 Wg/ml PMSF and
10 Wg/ml each of chymostatin, leupeptin and antipain
for 30 min at 4‡C [32]. The nuclear extracts were
centrifuged 10 min at 15 000Ug to remove insoluble
matter. The clari¢ed supernatants containing soluble
p53 were used in the immunoprecipitation reactions
described below.
Cytoplasmic proteins were extracted from un-
sorted bone marrow cells of p53+/+ mice (2U106/Wl
bu¡er). The cells were lysed in 20 mM HEPES, pH
7.4, 5 mM NaCl, 5 mM MgCl2, 0.5% NP-40, 0.05%
sodium azide, 0.1% sodium deoxycholate, 30 Wg/ml
BBAMCR 14474 25-5-99
J.L. Pipkin et al. / Biochimica et Biophysica Acta 1450 (1999) 164^176166
aprotinin, 1 mM PMSF (lysis bu¡er) [33] and centri-
fuged at 1500Ug in a Becton Dickinson Air Fuge for
10 min at 4‡C.
P53 was immunoprecipitated directly from the nu-
clear and cytoplasmic fractions (450 Wg protein and
1500 Wg protein, respectively). Wild type (wt) rat
p53-speci¢c monoclonal antibody Pab 246 was ob-
tained from Oncogene Science (Uniondale, NY) and
1 Wg portions were added to 25 Wl portions of each
sample aliquot. IgG-p53 immune complexes were al-
lowed to form for 5 h at 4‡C, then adsorbed to
immobilized Protein A-Sepharose (Pharmacia) [34].
The immobilized immune complexes were washed
three times by resuspension in sample bu¡er and
brief, gentle centrifugation. Immunoprecipitated pro-
teins were released from the adsorbed complexes us-
ing 1.5 M NaCl. The sample supernatants after cen-
trifugation were collected and dialyzed against IEF
cathodic electrophoresis bu¡er prior to analysis of
purity and recovery by two-dimensional PAGE and
£uorography.
2.7. Fluorescent labeling of stress proteins
Nuclei from BL-treated p53+/3 and p53+/+
mouse bone marrow cells were electrostatically
sorted to isolate nuclei only from G0+G1, with no
unbroken cells. Sps were extracted from the nuclei,
fractionated using preparative two-dimensional elec-
trophoretic gels, and eluted as described above
[19,29]. Eluted stress proteins were added to a reac-
tion bu¡er containing 50 mM KCl, 25 mM Tris (pH
7.5), and 2 mM MgCl [40]. The £uorescent dye N-
(iodoacetyl)-NP-1-sulfo-5-naphthylethylene-diamine
(Sigma) was dissolved in a minimal amount of N,NP-
dimethylformamide (DMF). Sp samples were labeled
with a 15^30-fold excess of £uorescent dye (10%
DMF, ¢nal) at 2‡C in the dark for 12 h [6,40]. The
£uorescently labeled proteins were dialyzed against
1000 vols. of p53 binding bu¡er (10 mM imidazole-
HCl, 0.2 mM ATP, 0.2 mM CaCl2, pH 8.0) for 24 h
at 2‡C as described for rabbit actin [40]. Aliquots
were subjected to one-dimensional SDS-PAGE anal-
ysis to verify purity and consistent incorporation of
the £uorescent dye. Additional aliquots were incu-
bated with immunoprecipitated p53 (described be-
low) and subjected to one-dimensional SDS-PAGE
analysis to verify that p53 binding activity was re-
tained.
2.8. Formation and analysis of p53 and sp complexes
Immunoprecipitated p53 was isolated from G0+G1
or S+G2/M nuclei of RA-treated p53+/+ mice. Stress
proteins of each class were extracted from the nuclei
of BL-induced p53+/+ and p53+/3 mice, fraction-
ated using two-dimensional gel electrophoresis, elec-
troeluted from gel plugs, renatured, and £uorescently
labeled as described above. Each binding reaction
consisted of 50 ng of unlabeled p53 plus 50 ng
£uorescently labeled stress protein in p53 binding
bu¡er (10 mM imidazole-HCl, 0.2 mM ATP,
0.2 mM CaCl2, pH 8.0). Complexes were allowed
to form for 30 min at room temperature, applied
to the ¢rst dimension (IEF) of two-dimensional
PAGE, and fractionated using an UMEA. After
the second dimension (non-denaturing PAGE), the
¢nished gels were scanned £uorimetrically.
2.9. Quantitation of the p53 and sp complex
The Microtech II digital system (NIH program)
and the Macintosh II computer were used to deter-
mine area (relative value) of the complex by counting
pixel numbers and measuring density of each. These
parameters were converted into a single relative value
for quantitation [38]. Three animals were used as
samples for a single condition (data point), and ¢ve
gels were run for a given sample.
3. Results
3.1. Two-dimensional PAGE of sps from p53+/3 and
p53+/+ mice
The synthesis patterns of p53 and of the sps were
examined by ultra-micro PAGE in mice bone mar-
row nuclei. Sps were induced by BL administration
and p53 by RA dosing. P53 was obtained by immu-
noprecipitation and gel puri¢cation [34,41], while sps
were isolated from gels following two-dimensional
PAGE [19,29,30]. The [35S]methionine incorporation
by sps is shown in Fig. 1. The sps were mostly syn-
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thesized in the G1 phase of the cell cycle
[6,7,16,19,42^47]; therefore, only this phase was pre-
sented in Fig. 1.
The control bone marrow cells from p53+/3 and
p53+/+ mice showed the constitutive forms of p53
and the cognate forms of sp 72 and 90 (Fig. 1A,B).
Following administration of BL, a powerful sp in-
ducer [16], synthesis of eight sps was initiated, and
the chaperones ranged in Mr from 22 000 to 100 000
in both p53+/3 and p53+/+ mice (Fig. 1C,D).
3.2. Western blot determination of the nuclear sps
Following separation of total nuclear proteins
from p53+/+ mice by two-dimensional UMEA
PAGE, the sps were identi¢ed individually in sepa-
rate Western blots by speci¢c commercial antibodies
(data not shown). The results of immunochemical
determinations with sp antibodies run simultaneously
and in combination with markers V and A3 are
shown in Fig. 2.
3.3. Two-dimensional PAGE of p53 synthesis during
cell cycling in the p53+/3 and p53+/+ mouse
The rectangle in Fig. 1A, which circumscribes the
location of p53, is enlarged 3.5U by computer imag-
ing and presented in Figs. 3 and 4. In the p53+/3
mice, the constitutive pattern of p53 (control, no
RA) showed the 35S labeling (synthesis) of isoforms
3 and 4 from the G1 phase of the cell cycle (Fig. 3A).
Examination of the S+G2 phase also revealed iso-
Fig. 1. Two-dimensional UMEA PAGE £uorograph of 35S incorporation (synthesis) patterns of imidazole bu¡er extracted nuclear
proteins from mouse bone marrow cells. Nuclei were sorted from the G1 phase of the cell cycle and the solubilized proteins (500 ng)
were separated in two-dimensional UMEA gels. (A) p53+/3, control (no BL, no RA); (B) p53+/+, control; (C) p53+/3, 2 h BL; (D)
p53+/+, 2 h BL. Arrow indicates p53 and R reference protein. The area delineated by the rectangle was examined by £uorography in
this ¢gure and in subsequent studies of p53. K act represents K-actinin (80 000 Mr, pI 5.8), La, Lc (lamin 70 000, 67 000 Mr, respec-
tively, pI 7.0), V (vimentin 58 000 Mr, pI 5.0), A3 (actin isoform #3, 43 000 Mr, pI 5.3). + represents the anode direction of electrical
current in the gel. The isoelectric points (pI) of the gel are shown at the bottom of this and other ¢gures.
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types 3 and 4 but which were synthesized to lesser
degrees (Fig. 3A1). The p53+/+ control mice of the
G1 phase showed incorporation of isoforms 3, 4 and
5 (Fig. 3B), and these isotypes were much reduced in
labeling at S+G2 phase (Fig. 3B1). Administration of
RA to p53+/3 mice increased 35S labeling of isotypes
3 and 4 and evoked synthesis of two additional iso-
forms [5,6] in the G1 phase (Fig. 3C). In the S+G2
phase, there was a reduced amount of 35S incorpo-
ration in isoforms 3 and 4 of p53+/3 mice (Fig.
3C1). Investigation of the p53+/+ mice following 36
h of RA dosing indicated intense 35S labeling of all
isoforms (3^9) during the G1 phase (Fig. 3D). The
labeling in the S+G2 phase was decreased generally
in all isoforms with dramatic reduction in 3 and 4
(Fig. 3D1).
3.4. Western blot analysis of the p53 isoforms in
p53+/3 and p53+/+ mice
The Pab 246 wt monoclonal antibody was used in
ultra-micro immunoblotting to con¢rm the identity
of the p53 isoforms from mouse bone marrow nuclei
during the cell cycle, following 36 h of RA in vivo
administration. The p53 isoforms detected by immu-
nochemical analysis, which re£ected 35S labeling
from the secondary antibody, in both p53+/3 and
p53+/+ control and RA dosed mice, were very sim-
ilar in composition and labeling intensities to the
isotype synthesis patterns observed in these same an-
imals (Fig. 4). For example, the isotype synthesis
patterns in the p53+/+ mice dosed with RA showed
substantially higher incorporation in the G1 and
S+G2 phases (Fig. 4) than the p53+/3 animals
(Fig. 3).
Fig. 2. Two-dimensional UMEA PAGE Western blot analysis
of sps. The unlabeled nuclear proteins (500 ng) from p53+/+
mice treated with BL, including protein markers V and A3,
were separated in UMEA by two-dimensional PAGE. Ultra-mi-
cro Western blot determination was done with unlabeled sp
antigen (bone marrow), unlabeled sp primary antibody (Stress-
Gen) and 35S-labeled secondary antibody (A⁄nity BioRe-
agents). Vimentin (V) antibody was obtained commercially and
actin isoform A3 antibody was made in our laboratory. These
markers were run in conjunction with the sps as reference pro-
teins.
Fig. 3. Two-dimensional UMEA PAGE £uorograph of 35S in-
corporation (synthesis) patterns of p53 isoforms from the G1
and S+G2 phases of mouse bone marrow cells. (A) p53+/3,
control, G1 ; (A1) p53+/3, control, S+G2 ; (B) p53+/+, control,
G1 ; (B1) p53+/+, control, S+G2 ; (C) p53+/3, 36 h RA, G1 ;
(C1) p53+/3, 36 h RA, S+G2 ; (D) p53+/+, 36 h RA, G1 ; (D1)
p53+/+, 36 h RA, S+G2. The £uorographs elucidating the syn-
thesis (this ¢gure) and antibody recognition (Fig. 4) patterns of
the p53 isoforms were enlarged 3.5U by computer imaging
from the area of the rectangle as represented in Fig. 1A. The
p53 isoforms are numbered at the top of the patterns and pI
values are indicated at the bottom in this and in subsequent ¢g-
ures.
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3.5. Two-dimensional UMEA PAGE of the
immunoprecipitated p53 complex and associated
proteins from the nuclear and cytoplasmic
fractions of animals treated with BL
Following immunoprecipitation of the p53 com-
plex from the nuclear fraction and two-dimensional
PAGE of the proteins, £uorography revealed p53
composed of seven distinctly labeled isoforms (3^9)
(Fig. 5A). Also co-precipitated with the complex
were four labeled sps designated by their Mr
U1033. These sps were identi¢ed by Western blot
determination from the immunoprecipitated complex
(not shown) which corresponded to those identi¢ed
in Fig. 2. An abundance of unidenti¢ed labeled pro-
teins was associated with the complex (non-speci¢c
labeling (NSL, arrows)).
The PAGE £uorograph of p53 immunoprecipi-
tated from the cytoplasmic fraction (Fig. 5B) was
similar in pattern to the nuclear fraction. However,
there was increased incorporation in p53 and the sps
in the cytoplasmic fraction. The labeling was so ro-
bust that p53 and the sp 70 family lost resolution.
Labeling of NSL was also increased.
3.6. One-dimensional PAGE of dye £uorescence of
separated proteins
The proteins that were isolated from two-dimen-
sional gels and tagged with dye appeared as well
di¡erentiated single bands that signi¢ed their purity
following electrophoresis (Fig. 6). These sps were
used for subsequent binding studies with p53. V
and A3 were tagged and used as molecular marker
proteins.
3.7. One-dimensional PAGE of isolated proteins silver
stained and/or tagged with £uorescence dye
The interaction of sp 90 and p53 was compared by
silver staining and/or tagging with £uorescence dye
(Fig. 7). In gel 1, the position of p53, sp 90 and
p53+sp 90 are shown after silver staining. The com-
plex of p53 and sp 90 was increased in molecular
mass and was seen as a larger band with the slowest
mobility. Unbound sp 90 and p53 have faster mobi-
lities than their bound counterparts. In gel 2, p53
was not visually resolved (not tagged) and sp 90
(tagged, not bound to p53) was seen as a single
band. The p53 and sp 90 complex appeared as a
slower migrating larger, single band. The £uores-
cence of the complex was attributed to dye tagged
sp 90.
3.8. Binding of p53 isoforms with sps
Electrophoresis was employed to examine the
binding of p53 isoforms with individual sps that
were tagged with £uorescence dye. This association
was re£ected in the £uorescence of the dye tagged sps
after binding with the p53 isoforms of the complex
(p53+sp) following UMEA PAGE.
Sp 90 of the p53+/3 mouse showed binding to p53
isoforms 3, 4, 5 and 6 during the G1 phase (Fig. 8A).
Isoform 3 was weakly £uorescent (bound). During
S+G2 only isotype 6 was weakly bound (Fig. 8A1).
Sp 90 (p53+/+) showed binding of isoforms 3^9 dur-
ing the G1 phase (Fig. 8B), and at S+G2 these iso-
Fig. 4. Two-dimensional UMEA PAGE Western blot analysis
of the Pab 246 rat wt monoclonal antibody reacted with p53
isoforms from p53+/3 and p53+/+ mouse bone marrow cells.
(A) p53+/3, control, G1 ; (A1) p53+/3, control, S+G2 ; (B)
p53+/+, control, G1 ; (B1) p53+/+, control, S+G2 ; (C) p53+/3,
36 h RA, G1 ; (C1) p53+/3, 36 h RA, S+G2 ; (D) p53+/+, 36 h
RA, G1 ; (D1) p53+/+, 36 h RA, S+G2.
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forms gave a similar binding pattern; however, 3, 4
and 5 demonstrated reduced £uorescence (Fig. 8B1).
Sp 72c (p53+/3) from the G1 phase denoted bind-
ing to p53 isoforms 3, 4, 5 and 6 with 3 possessing
low £uorescence (Fig. 8C). During S+G2, binding
was reduced to two isotypes, 5 and 6 (Fig. 8C1).
Sp 72c (p53+/+) of the G1 phase showed robust £u-
orescence in isoforms 3^9 (Fig. 8D), and at S+G2,
the overall £uorescence was reduced with 3 and 4
isoforms being dramatically decreased (Fig. 8D1).
Sp 70i (p53+/3) revealed binding to isoforms 3, 4,
5 and 6 in G1 phase (Fig. 8E) and binding to only
isoform 6 was observed in S+G2 (Fig. 8E1). Sp 70i
(p53+/+) demonstrated modest binding to all iso-
forms (3^9), during G1 phase (Fig. 8F), and the £u-
orescence was decreased substantially in isoforms 6,
7, 8 and 9 in S+G2 (Fig. 8F1). Isotypes 3, 4 and 5
were not present during this phase.
Sp 25a (p53+/3) bound with 3, 4, 5 and 6 of p53
in G1 phase (Fig. 8G), and during S+G2 only isotype
6 was seen with reduced £uorescence (Fig. 8G1). Sp
25a (p53+/+) manifested modest binding of all iso-
Fig. 5. Two-dimensional UMEA PAGE of immunoprecipitated p53 complex and associated proteins from p53+/+ mice following 36
h of RA administration and [35S]methionine in vivo labeling. (A) The p53 Pab 246 wt antibody was used for immunoprecipitation
from the nuclear fraction and the immune complex associated with p53 was analyzed by UMEA two-dimensional gels. The sps are in-
dicated by Mr U1033 and non-speci¢c labeling (NSL) is indicated by arrows. (B) p53 and sps co-immunoprecipitated from the cyto-
plasmic fraction of unsorted bone marrow cells as described in A. 500 ng of p53 immunoprecipitated complex from the nuclear and
cytoplasmic fractions were used in each £uorograph.
Fig. 6. One-dimensional UMEA PAGE isolated nuclear pro-
teins. Sps, vimentin (V) and actin (A3) from mouse bone mar-
row cells were isolated and puri¢ed from preparative gels (220
units). All proteins (30 ng each) were tagged with £uorescent
dye and run simultaneously in a one-dimensional SDS gel.
Fig. 7. One-dimensional UMEA PAGE of isolated protein sil-
ver stained and/or £uorescently tagged. Sp 90 was isolated and
puri¢ed from preparative gels (220 units) and p53 was immuno-
precipitated and further puri¢ed from gels (220 units). Gel 1,
silver staining of sp 90 (30 ng)+p53 (30 ng); gel 2, sp 90 was
tagged with £uorescence dye while p53 was not: sp 90 (30
ng)+p53 (30 ng). Non-denaturing gels were used in both gel 1
and 2 experiments.
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forms (3^9) of the G1 phase (Fig. 8H), and at S+G2
this £uorescence was seen only in 6, 7, 8 and 9 (Fig.
8H1). Isotypes 3 and 4 disappeared at this phase.
Binding of the £uorescently tagged sps with p53
did not alter the overall net charge of the latter pro-
tein following electrophoresis. However, the Mr of
the complex was substantially increased from that
of unbound p53.
Bovine serum albumin fraction V (tagged, 30 ng),
phosphorylase b (tagged, 30 ng) and ovalbumin
(tagged, 30 ng) were mixed separately with p53
(not tagged, 30 ng) in solvent bu¡er and run in dif-
ferent PAGE lanes as controls. There was no binding
between these control proteins and p53 (data not
shown). Sp 22, 23, 25b and 100 (p53+/3 and p53+/
+ mice) responded similarly to the control proteins
indicating no detectable binding with p53.
3.9. Quantitation of the p53 and sp complex
The binding levels of p53 and sps (£uorescence
complex) in 2-month-old p53+/3 and p53+/+ mice
were quanti¢ed as relative values. The p53 and sp
complex from the G1 phase of the cell cycle was
Fig. 8. Two-dimensional UMEA PAGE of £uorescence binding analysis of isolated sps and p53. Sps (50 ng each) were tagged with
£uorescent dye and p53 (50 ng) was not tagged in binding studies. (A) sp 90+p53, +/3, G1 ; (A1) sp 90+p53, +/3, S+G2 ; (B) sp
90+p53, +/+, G1 ; (B1) sp 90+p53, +/+, S+G2 ; (C) sp 72c+p53, +/3, G1 ; (C1) sp 72c+p53, +/3, S+G2 ; (D) sp 72c+p53, +/+, G1 ;
(D1) sp 72c+p53, +/+, S+G2 ; (E) sp 70i+p53, +/3, G1 ; (E1) sp 70i+p53, +/3, S+G2 ; (F) sp 70i+p53, +/+, G1 ; (F1) sp 70i+p53, +/
+, S+G2 ; (G) sp 25a+p53, +/3, G1 ; (G1) sp 25a+p53, +/3, S+G2 ; (H) sp 25a+p53, +/+, G1 ; (H1) sp 25a+p53, +/+, S+G2.
Table 1
Relative value of the p53 and sp complex from 2-month-old mice G1 phase
Fig. 8 A B C D E F G H
Genetic complement of animals +/3 +/+ +/3 +/+ +/3 +/+ +/3 +/+
Stress protein 90 90 72c 72c 70i 70i 25a 25a
Relative valuea 595 1635 633 2726 468 1012 220 1313
S.D. þ 18.3 þ 172 þ 22.4 þ 241 þ 14.6 þ 89.3 þ 7.32 þ 117 þ
aRelative value of the £uorescence complex (p53 and sp) was calculated from pixel numbers and their densities from three animals of
the same strain.
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measured and in every instance the complex from
p53+/+ animals indicated a signi¢cant increase in
binding when compared with p53+/3 animals (Table
1). Furthermore, these values showed binding a⁄n-
ities which were sp speci¢c, i.e., sp 72c had the great-
est association with p53 and sp 70i the smallest.
4. Discussion
It is postulated that cellular homeostasis is main-
tained by sps following natural and arti¢cial trau-
matic events (reviewed in [48,49]). In addition, they
function in normal protein synthesis and transport of
polypeptides [50]. We have reported previously the
induction of sps in rodent cells of various tissue ori-
gins following heat shock and environmental shifts
[51^53], teratogens [24,42,47,54], and treatment with
drugs and chemicals [16,19,22,24,37^39,44,53,55].
The eight sps induced in this present study showed
no di¡erences in their synthesis patterns between
mice of the two genotypes. Therefore, this study in-
dicates that the presence of only one-half of the p53
genetic complement has no e¡ect on normal sp syn-
thesis levels in the p53+/3 mouse.
RA evoked the synthesis of nuclear p53 isoforms
to a greater extent in p53+/+ relative to p53+/3 ani-
mals. Furthermore, di¡erential synthesis of isotypes
revealed cell cycle regulated dependence. That is, the
increased synthesis of the p53 isoforms was greater in
the G1 than in the S+G2 phase in both p53+/3 and
p53+/+ animals exposed either to the diluent or to
RA. The increased synthesis of p53 isotypes was due
to the appearance of additional polypeptides that
were more acidic in their overall net charge. An in-
crease in acidic p53 isoforms has also previously been
observed following their induction [13,56,57]. We re-
ported a similar pattern of p53 isoform increase (syn-
thesis) from the G1 phase in rats during a diet re-
striction study [2]. However, we did not observe the
dramatic cell cycle regulated di¡erences in the syn-
thesis level of p53 isotypes in rats following RA dos-
ing as reported here in mice.
P53 is a regulator cellular polypeptide that func-
tions at the critical G1/S juncture in the mitotic path-
way. It operates to halt cell cycle progression at this
interface either by blocking DNA replication directly
or by interfering indirectly with genes necessary for
the completion of somatic cell division [15,58^60].
P53 forms functional units (complexes) with sps, pri-
marily attributed to the binding properties of the
latter proteins [61]. In addition, it has been docu-
mented that sps forms essential biological associa-
tions with numerous polypeptides besides p53. For
example, sp 90 is an element of the estrogen receptor
complex which functions as a transient agent that is
released when an estrogen ligand binds to the recep-
tor complex [62]. During normal protein synthesis,
the 70 chaperone family folds nascent aliphatic poly-
peptides into their proper con¢guration, and under
abnormal conditions, refolds damaged protein mole-
cules into their original tertiary structure [50]. Re-
cently, the binding of sps was reported in association
with p53, forming a complex that was immunopre-
cipitated from the cytoplasmic fraction [13,15]. This
association between sps and p53 has been theorized
as a mechanism for protecting p53 from protease
activity in the cytoplasm [14,15]. This complexing
with sps may also alter the conformation of p53
thus enabling the molecule to function as a cell cycle
inhibitor [14]. Of equal importance is the fact that
sps may act as a vehicle for transport of p53 to the
nucleus [63,64] where p53 disassociates from these
chaperones [13,15]. This would allow the free p53
molecule to bind with DNA, thus exerting its regu-
latory in£uence.
It is noteworthy that the untreated control mice
(p53+/3 and p53+/+) in our study did not produce
sp/p53 aggregations. However, with RA dosing, four
sps were bound to p53 following immunoprecipita-
tion of the complex. Perhaps the reduction in cell
cycling by RA could alter p53 from its control (no
RA) con¢guration (i.e., increase isoforms) and pro-
mote binding of these two diverse proteins. As re-
ported elsewhere [14,15] and con¢rmed by us (data
not shown), p53 was not detected in the p533/3 null
mouse.
Diverse data have been published by workers re-
garding the existence of the inducible form of sp 70
(70i) complexed with p53. For example, the associa-
tion of sp 70i (Hsx 70) with p53 has been docu-
mented by some workers [65,66]; however, others
have reported only 72c present in the complex
[15,67^70]. Besides sp 70, sp 90 was bound with the
same p53 complex [15,71]. We have observed by
PAGE robust labeling of sps 70i, 72c and 90 in the
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p53 complex which was co-immunoprecipitated from
the cytoplasmic fractions. Thus, we have con¢rmed
the presence of 70i in the p53 complex. Also, we
report here as a premier event, the co-precipitation
of a fourth sp (25a) identi¢ed as an isoform of sp25.
In addition, we report that the p53 cytoplasmic frac-
tion has a 10-fold greater labeling level of sps com-
pared to the nuclear fraction following RA dosing.
Others have failed to resolve even small levels of sps
associated with the nuclear p53 complex [13]. Our
data may signify that the p53 complex exists in two
pools: a static major cytoplasmic pool and a minor
£uctuating nuclear pool. A continuing reservoir may
reside at high levels in the cytoplasm, and as p53
elements of the complex transgress through the nu-
clear pores, rapid disassociation occurs accounting
for the minor pool. This scenario is re£ected in low
abundance of these chaperones in the nuclear frac-
tion as exhibited in our PAGE £uorographs.
Sps 25a, 70i, 72c and 90 all co-precipitated in the
p53 complex, and all exhibited binding with p53
when analyzed in the £uorescence-dye assay. They
demonstrated greater £uorescence (binding) with
the isoforms in p53+/+ than in p53+/3 mice. Con-
versely, there was greater isoform reduction in the
p53+/3 than in the p53+/+ mouse that constituted
loss of £uorescence from the more basic isotypes.
Increased synthesis of p53 in both groups of animals
following RA administration entailed 35S incorpora-
tion primarily of the more acidic isoforms, and the
increased binding with sps was seen in synonymous
isoforms. Furthermore, these two events were more
pronounced in the G1 phase, the partition of the cell
cycle where p53 is purported to exert its regulatory
in£uence [72,73]. Sps 25a, 70i and 90 demonstrated
levels of binding not greatly di¡erent from each other
during cell cycling. However, sp 72c showed robust
£uorescence in both G1 and S+G2 phase. The inclu-
sion of sps in the p53 complex seemed to be an
essential property for in vitro binding with the p53
isotypes. Namely, sp 22, 23, 25b and 100 (not immu-
noprecipitated by the p53 antibody) showed no bind-
ing a⁄nity with p53 isoforms when examined in the
in vitro £uorescence-dye assay (data not shown).
In summary, sps may possess multiple functional
roles in their alliance with p53. They may serve in
transport and protection as described above, and
they may prime p53 for its regulatory activity that
constitutes interference with cell cycle kinetics. More
speci¢cally, upon entering the nucleus, the majority
of the sps may dislodge from the p53 binding sites
thereby dramatically reducing the nuclear complex
pool. The balance of sps that remain also may dis-
associate from p53 after altering the con¢guration
and conditioning the regulator protein for interaction
with genes programmed for cell cycle dynamics.
It has been reported that synthesis and phospho-
rylation were closely coupled during functional activ-
ities of p53 [2,9,57]. Here, we report only the mani-
festation of p53 expression. We are currently
investigating phosphorylation of p53 in the cytoplas-
mic and nuclear fractions of the p53+/3 and p53+/+
mouse model to understand more fully the regulatory
properties of this intriguing protein. The di¡erential
binding of sps with p53 may re£ect those isoforms
primed for regulation.
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